Status:
TERMINATED
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including Lopinavir/ritonavir (LPV/RTV), ...
Eligibility Criteria
Inclusion
- \- Documented Metabolic Syndrome by at least 3 of the following parameters:
- Abdominal obesity, assessed by waist circumference (for men \>103 cm, for women \>88 cm).
- Triglycerides \> 150 mg/dl.
- HDL cholestrol (for men \<40 mg/dl, for women \<50 mg/dl).
- Blood pressure \> or equal to 130/85 mm Hg.
- Fasting serum glucose \> or equal to 110 mg/dl.
- HIV RNA \< 50 copies/mL.
- IP within 3 months prior to selection.
Exclusion
- Treated Metabolic Syndrom
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00312754
Start Date
June 1 2005
End Date
April 1 2007
Last Update
September 19 2016
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Bobigny, France, 93009
2
Local Institution
Le Kremlin-Bicêtre, France, 94270
3
Local Institution
Paris, France, 75651
4
Local Institution
Paris, France, 75877